Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
November 30, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022 09:31 ET
|
Autolus Therapeutics plc
obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
November 03, 2022 07:00 ET
|
Autolus Therapeutics plc
Pivotal FELIX Phase 2 clinical trial of obe-cel in relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) on track for Q4 2022 updateCommercial manufacturing site build on schedule for handover...
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 07:54 ET
|
Autolus Therapeutics plc
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON,...
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
July 06, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
June 10, 2022 03:01 ET
|
Autolus Therapeutics plc
- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...